Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Dec 21

PMID 33344247

Citations 2

Authors

Timothy W Farren

Kaushik S Sadanand

Samir G Agrawal

Affiliations

Soon will be listed here.

Abstract

Undetectable minimal residual disease (MRD) in Chronic Lymphocytic Leukemia (CLL) has a favorable prognostic outcome compared with MRD that can be detected. This study investigated a flow cytometric assay (CD160-ROR1FCA) targeting the tumor-specific antigens CD160 and receptor tyrosine kinase-like orphan receptor 1 (ROR1), along with CD2, CD5, CD19, CD45. CD160-ROR1FCA was compared with the originally published 8-colour European Research Initiative for CLL (ERIC) gold-standard assay for CLL MRD detection. CD160-ROR1FCA had a limit of detection of 0.001% and showed strong correlation with ERIC ( = 0.98, p < 0.01) with negligible differences in MRD detection (bias -0.3152 95%CI 5.586 to -6.216). Using CD160-ROR1FCA, increased expression of both CD160 and ROR1 was found in Monoclonal B cell Lymphocytosis (MBL) compared to low-level polyclonal B-cell expansions (p < 0.01). Patients in CR and with undetectable MRD had a longer EFS (not reached) than those in CR but with detectable MRD (756 days, p < 0.01) versus 113 days in patients with partial remission (p < 0.01). Patients with MRD levels of >0.01 to 0.1% had a longer EFS (2,333 days), versus levels between 0.1 to 1% (1,049 days). CD160-ROR1FCA is a novel assay for routine CLL MRD measurement and for MBL detection. MRD status assessed by CD160-ROR1FCA after CLL treatment correlated with EFS.

Citing Articles

CD160 receptor in CLL: Current state and future avenues.

Oumeslakht L, Aziz A, Bensussan A, Ben Mkaddem S Front Immunol. 2022; 13:1028013.

PMID: 36420268 PMC: 9676924. DOI: 10.3389/fimmu.2022.1028013.

ROR1: an orphan becomes apparent.

Kipps T Blood. 2022; 140(14):1583-1591.

PMID: 35580162 PMC: 10653015. DOI: 10.1182/blood.2021014760.

References

Seymour J, Kipps T, Eichhorst B, Hillmen P, DRozario J, Assouline S . Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2018; 378(12):1107-1120. DOI: 10.1056/NEJMoa1713976. View

Rawstron A, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder J . International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21(5):956-64. DOI: 10.1038/sj.leu.2404584. View

Farren T, Giustiniani J, Fanous M, Liu F, Macey M, Wright F . Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J. 2015; 5:e273. PMC: 4314455. DOI: 10.1038/bcj.2014.92. View

Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch R, Fingerle-Rowson G . Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30(9):980-8. DOI: 10.1200/JCO.2011.36.9348. View

Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M . A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor. J Exp Med. 2011; 208(5):973-86. PMC: 3092350. DOI: 10.1084/jem.20100810. View

Oscier D, Dearden C, Eren E, Erem E, Fegan C, Follows G . Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012; 159(5):541-64. DOI: 10.1111/bjh.12067. View

Liu F, Giustiniani J, Farren T, Jia L, Bensussan A, Gribben J . CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia. Blood. 2010; 115(15):3079-88. PMC: 5292590. DOI: 10.1182/blood-2009-08-239483. View

Campana D . Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011; 2010:7-12. DOI: 10.1182/asheducation-2010.1.7. View

Uhrmacher S, Schmidt C, Erdfelder F, Poll-Wolbeck S, Gehrke I, Hallek M . Use of the receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a diagnostic tool in chronic lymphocytic leukemia (CLL). Leuk Res. 2011; 35(10):1360-6. DOI: 10.1016/j.leukres.2011.04.006. View

10.

Paietta E . Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?. Bone Marrow Transplant. 2002; 29(6):459-65. DOI: 10.1038/sj.bmt.1703388. View

11.

Furman R, Sharman J, Coutre S, Cheson B, Pagel J, Hillmen P . Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370(11):997-1007. PMC: 4161365. DOI: 10.1056/NEJMoa1315226. View

12.

Farren T, Giustiniani J, Liu F, Tsitsikas D, Macey M, Cavenagh J . Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood. 2011; 118(8):2174-83. PMC: 5292591. DOI: 10.1182/blood-2011-02-334326. View

13.

Broome H, Rassenti L, Wang H, Meyer L, Kipps T . ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia. Leuk Res. 2011; 35(10):1390-4. PMC: 3163753. DOI: 10.1016/j.leukres.2011.06.021. View

14.

Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G . Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019; 380(22):2095-2103. PMC: 11827445. DOI: 10.1056/NEJMoa1900574. View

15.

Riches J, Davies J, McClanahan F, Fatah R, Iqbal S, Agrawal S . T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2012; 121(9):1612-21. PMC: 3587324. DOI: 10.1182/blood-2012-09-457531. View

16.

Choudhury A, Derkow K, Daneshmanesh A, Mikaelsson E, Kiaii S, Kokhaei P . Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol. 2010; 151(4):327-35. DOI: 10.1111/j.1365-2141.2010.08362.x. View

17.

Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, Siewiera J . CD160: a unique activating NK cell receptor. Immunol Lett. 2011; 138(2):93-6. DOI: 10.1016/j.imlet.2011.02.003. View

18.

Karvonen H, Chiron D, Niininen W, Ek S, Jerkeman M, Moradi E . Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Adv. 2018; 1(24):2257-2268. PMC: 5737127. DOI: 10.1182/bloodadvances.2017010215. View

19.

Rai K, Peterson B, Appelbaum F, Kolitz J, Elias L, Shepherd L . Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343(24):1750-7. DOI: 10.1056/NEJM200012143432402. View

20.

Wood B . Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry. Cytometry B Clin Cytom. 2015; 90(1):47-53. DOI: 10.1002/cyto.b.21239. View